A Phase II, Open-label, Multicenter Study Evaluating the Efficacy of Imatinib Plus Hydroxyurea (HU) in Patients With Progressive Glioblastoma Multiforme (GBM) Receiving or Not Receiving Enzyme-inducing Anticonvulsant Drugs (EIACDs)
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Imatinib (Primary) ; Hydroxycarbamide
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Novartis
- 16 Jun 2011 New source identified and integrated (European Clinical Trials Database; EudraCT2005-002600-41).
- 16 Jun 2011 New source identified and integrated (European Clinical Trials Database; EudraCT2005-002600-41).
- 13 May 2011 Planned end date added 1 Aug 2008 as reported by ClinicalTrials.gov.